Anti-FAP CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania)

N/A

Report date: 2024/05/11 18:35:18

Base Information

Drug NameAnti-FAP CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania)

Drug Alias NameTmFAP 01 CAR-T

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Prolyl endopeptidase FAPT lymphocyte replacementsImmunologic cytotoxicity

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania Tmunity Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesTmunity Therapeutics Inc University Of Pennsylvania

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A